Patents Assigned to DDI Pharmaceuticals, Inc.
  • Patent number: 5283317
    Abstract: A biologically persistent, water-soluble, substantially non-immunogenic, substantially non-antigenic conjugate of superoxide dismutase is prepared by coupling one to five strands of a polyalkylene glycol which is polyethylene glycol or polyethylene-polypropylene glycol copolymer, wherein said polyalkylene glycol has an average molecular weight of about 35,000-1,000,000.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: February 1, 1994
    Assignee: DDI Pharmaceuticals, Inc.
    Inventors: Mark Saifer, Ralph Somack, L. David Williams
  • Patent number: 5080891
    Abstract: A biologically persistent, water-soluble, substantially non-immunogenic, substantially non-antigenic conjugate of superoxide dismutase is prepared by coupling one to five strands of a polyalkylene glycol which is polyethylene glycol or polyethylene-polypropylene glycol copolymer, wherein said polyalkylene glycol has an average molecular weight of about 35,000-1,000,000.
    Type: Grant
    Filed: August 1, 1990
    Date of Patent: January 14, 1992
    Assignee: DDI Pharmaceuticals, Inc.
    Inventors: Mark Saifer, Ralph Somack, L. David Williams
  • Patent number: 5006333
    Abstract: A biologically persistent, water-soluble, substantially non-immunogenic, substantially non-antigenic conjugate of superoxide dismutase is prepared by coupling one to five strands of a polyalkylene glycol which is polyethylene glycol or polyethylene-polypropylene glycol copolymer, wherein said polyalkylene glycol has an average molecular weight of about 35,000-1,000,000.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: April 9, 1991
    Assignee: DDI Pharmaceuticals, Inc.
    Inventors: Mark Saifer, Ralph Somack, L. David Williams